Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Contáctese con el equipo de la transacción
SHS has sold Spiegelberg to Luciole Medical AG
SHS and a minority co-shareholder have sold Spiegelberg GmbH to Luciole Medical AG.Ver más
Ecorobotix has completed a fundraising
Ecorobotix has raised US$52 million. The new capital will enable the company to grow into new markets, expand its product range and build on the existing commercial success of ARA in Europe.Ver más
Presmed Australia has been acquired by ICG
Advanced Health Limited has sold Presmed Australia Pty Ltd (PMA) to ICG.Ver más